News | June 10, 2022

Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) June 10, 2022 at 7:00 AM EDT All patients treated with bezuclastinib achieved ≥50% reduction in...